Showing posts with label Cancer Research UK. Show all posts
Showing posts with label Cancer Research UK. Show all posts

Friday, April 11, 2014

Prostate Cancer : Research finds more than half of a group of men whose cancer was classified as slow-growing turned out to be more dangerous

Prostate cancer tests underestimate aggressiveness of disease, says study


A surgeon sitting in front of screens of a Focal One device performs a prostate tumorectomy.
A surgeon sitting in front of screens of a Focal One device performs a robot-assisted prostate tumorectomy. Photograph: Jeff Pachoud/AFP/Getty Images

Men with prostate cancer are being given false hope by tests that underestimate the aggressiveness of their disease, according to a study.
Researchers found that more than half of a group of men whose cancers were initially classified as slow-growing and confined later turned out to have more dangerous tumours.
The findings, published in the British Journal of Cancer, call into question the ability of experts to grade and stage prostate cancers on the basis of biopsy samples.
It also casts doubt on the "active surveillance" strategy of avoiding unnecessary radical treatment for patients with slow-growing prostate cancer.
Instead, these patients are closely monitored but left alone until tests suggest their condition has worsened.
Urological surgeon Greg Shaw, from the Cancer Research UK Cambridge Institute, said: "Our results show that the severity of up to half of men's prostate cancers may be underestimated when relying on tests before they have surgery."
Slow-growing prostate cancers, known as "pussycats", are very different from the more aggressive "tiger" variety.
In some cases, especially when he is older when diagnosed, a patient can live to the end of his normal life span before a "pussycat" cancer becomes a threat.
An aggressive "tiger", on the other hand, may quickly spread if it is not surgically removed or destroyed.
Biopsy samples examined under a microscope are used to rate prostate tumour aggressiveness with a score ranging from two to 10. A score of between two and six is a low-grade "pussycat". A score of seven is intermediate, while scores of eight to 10 are high-grade "tigers".
Tumours are also staged according to how far they have spread. A T2 tumour is contained completely inside the prostate gland, while a T3 tumour has started to break out, and one classified T4 has spread to other organs or sites in the pelvic cavity.
The Cambridge scientists compared the staging and grading of more than 800 men's cancers before and after they had surgery to remove their prostate.
They found that of 415 patients whose cancer was classified as slow-growing and confined to the prostate, just over half (209) were found to have a more aggressive disease than originally thought when assessed after surgery.

Read More Here
Enhanced by Zemanta

Thursday, October 3, 2013

Resveratrol ,a chemical found in red wine remains effective at fighting cancer even after the body's metabolism has converted it into other compounds.

File:Vino-atardecer.jpg

Image source  :  Wikimedia . Org
By  jenny downing
***************************************************************


Red Wine Chemical, Resveratrol, Remains Effective Against Cancer After the Body Converts It

Oct. 2, 2013
This is an important finding in a new paper published in the journal Science Translational Medicine by Cancer Research UK-funded researchers at the University of Leicester's Department of Cancer Studies and Molecular Medicine.
The paper reveals that resveratrol -- a compound extracted from the skins of red grapes -- is not rendered ineffective once it is metabolised by the body.
This is an important development, as resveratrol is metabolised very quickly -- and it had previously been thought that levels of the extracted chemical drop too quickly to make it usable in clinical trials.
The new research shows that the chemical can still be taken into cells after it has been metabolised into resveratrol sulfates.
Enzymes within cells are then able to break it down into resveratrol again -- meaning that levels of resveratrol in the cells are higher than was previously thought.
In fact, the results appear to show resveratrol may be more effective once it has been generated from resveratrol sulfate than it is if it has never been metabolised because the concentrations achieved are higher.
The team, led by University of Leicester translational cancer research expert Professor Karen Brown, administered resveratrol sulfate to mice models.
They were subsequently able to detect free resveratrol in plasma and a variety of tissues in the mice.
This is the first direct sign that resveratrol can be formed from resveratrol sulfate in live animals, and the researchers think it may help to show how resveratrol is able to have beneficial effects in animals.
The study also showed that resveratrol generated from resveratrol sulfate is able to slow the growth of cancer cells by causing them to digest their own internal constituents and stopping them from dividing.
Professor Karen Brown said: "There is a lot of strong evidence from laboratory models that resveratrol can do a whole host of beneficial things -- from protecting against a variety of cancers and heart disease to extending lifespan.
"It has been known for many years that resveratrol is rapidly converted to sulfate and glucuronide metabolites in humans and animals -- meaning the plasma concentrations of resveratrol itself quickly become very low after administration.
"It has always been difficult to understand how resveratrol is able to have activity in animal models when the concentrations present are so low, and it has made some people skeptical about whether it might have any effects in humans.
"Researchers have hypothesized for a long time that resveratrol might be regenerated from its major metabolites in whole animals but it has never been proven.
"Our study was the first to show that resveratrol can be regenerated from sulfate metabolites in cells and that this resveratrol can then have biological activity that could be useful in a wide variety of diseases in humans.
"Importantly, we did all our work with clinically achievable concentrations so we are hopeful that our findings will translate to humans.
"Overall, I think our findings are very encouraging for all types of medical research on resveratrol. They help to justify future clinical trials where, previously, it may have been difficult to argue that resveratrol can be useful in humans because of the low detectable concentrations.
"There is considerable commercial interest in developing new forms of resveratrol that can resist or overcome the issue of rapid metabolism. Our results suggest such products may not actually be necessary to deliver biologically active doses of resveratrol to people."
Dr Sarah Williams, Cancer Research UK health information officer, said: "This interesting study supports continued research into resveratrol as a therapeutic molecule, but it's important to note that any benefits from the molecule don't come from drinking red wine. It's well established that drinking any type of alcohol, including red wine, increases the risk of developing cancer."
The study was carried out over eight years, and was funded by the Cancer Research UK and National Institute for Health Research (NIHR) Experimental Cancer Medicine Centre in Leicester, and the US National Cancer Institute.

Story Source:
The above story is based on materials provided by University of Leicester, via AlphaGalileo.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:
  1. Ketan R. Patel, Catherine Andreadi, Robert G. Britton, Emma Horner-Glister, Ankur Karmokar, Stewart Sale, Victoria A. Brown, Dean E. Brenner, Rajinder Singh, William P. Steward, Andreas J. Gescher and Karen Brown. Sulfate Metabolites Provide an Intracellular Pool for Resveratrol Generation and Induce Autophagy with Senescence. Science Translational Medicine, 2013 DOI: 10.1126/scitranslmed.3005870
Enhanced by Zemanta